Abstract
Extracellular vesicles (EVs) have been implicated in tumorigenesis. Biomolecules which can block EV binding and uptake into recipient cells may be of therapeutic value as well as enhance understanding of EV biology. Here, we show that heparin interacts with uptake of tumor-derived as well as non-tumor-derived EVs into recipient cells. Incubation of glioma cell-derived EVs with heparin resulted in micron-sized structures observed by transmission electron microscopy, with EVs clearly visible within these structures. Inclusion of heparin greatly diminished transfer of labeled EVs from donor to recipient tumor cells. We also show a direct interaction between heparin and EVs using confocal microscopy. We found that the block in EV uptake was at the level of cell binding and not internalization. Finally, incubation of glioma-derived EVs containing EGFRvIII mRNA with heparin reduced transfer of this message to recipient cells. The effect of heparin on EVs uptake may provide a unique tool to study EV function. It may also foster research of heparin or its derivatives as a therapeutic for disease in which EVs play a role.
MeSH Terms
Anticoagulants/pharmacology
ErbB Receptors/genetics,metabolism
Extracellular Space/drug effects
Flow Cytometry
Glioblastoma/drug therapy,metabolism,pathology
Heparin/pharmacology
Humans
RNA, Messenger/genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Transport Vesicles/drug effects
Tumor Cells, Cultured
Chemicals
Anticoagulants
RNA, Messenger
epidermal growth factor receptor VIII
Heparin
ErbB Receptors
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Atai Nadia A
Department of Neurology and Program in Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Balaj Leonora
van Veen Henk
Breakefield Xandra O
Jarzyna Peter A
Van Noorden Cornelis J F
Skog Johan
Maguire Casey A
References (28)
28 references, click to expand
-
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
Nat Cell Biol. 2008 Dec;10(12):1470-6
PMID: 19011622
-
Exosomes: composition, biogenesis and function.
Nat Rev Immunol. 2002 Aug;2(8):569-79
PMID: 12154376
-
Inhibition of metastases by anticoagulants.
J Natl Cancer Inst. 1999 Jan 6;91(1):22-36
PMID: 9890167
-
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
Cancer Res. 2007 Aug 1;67(15):7458-66
PMID: 17671216
-
Isolation and identification of histone H3 protein enriched in microvesicles secreted from cultured sebocytes.
Endocrinology. 2005 Jun;146(6):2593-601
PMID: 15746254
-
Clinical studies with anticoagulants to improve survival in cancer patients.
Pathophysiol Haemost Thromb. 2008;36(3-4):204-11
PMID: 19176993
-
Microvesicle-associated AAV vector as a novel gene delivery system.
Mol Ther. 2012 May;20(5):960-71
PMID: 22314290
-
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7
PMID: 11248082
-
Preventing growth of brain tumors by creating a zone of resistance.
Mol Ther. 2008 Oct;16(10):1695-702
PMID: 18714312
-
Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles.
Immunol Res. 2006;36(1-3):247-54
PMID: 17337785
-
Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group.
Cancer. 1994 Jul 1;74(1):38-45
PMID: 8004580
-
Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates?
Braz J Med Biol Res. 1999 May;32(5):529-38
PMID: 10412563
-
Microvesicles: messengers and mediators of tumor progression.
Cell Cycle. 2009 Jul 1;8(13):2014-8
PMID: 19535896
-
Mechanisms of heparin induced anti-cancer activity in experimental cancer models.
Crit Rev Oncol Hematol. 2007 Mar;61(3):195-207
PMID: 17074500
-
Experimental and clinical effects of anticoagulants on cancer progression.
Thromb Res. 2010 Apr;125 Suppl 2:S77-9
PMID: 20434011
-
Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.
Nat Cell Biol. 2012 Jun 03;14(7):677-85
PMID: 22660413
-
The effects of unfractionated heparin on survival in patients with malignancy--a systematic review.
Thromb Haemost. 1999 Dec;82(6):1600-4
PMID: 10613641
-
Functional delivery of viral miRNAs via exosomes.
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33
PMID: 20304794
-
Management of venous thromboembolism.
N Engl J Med. 1996 Dec 12;335(24):1816-28
PMID: 8943165
-
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences.
Nat Commun. 2011 Feb 01;2:180
PMID: 21285958
-
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
PMID: 23095881
-
The potential of exosomes in immunotherapy.
Expert Opin Biol Ther. 2005 Jun;5(6):737-47
PMID: 15952905
-
Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin.
Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7
PMID: 19261492
-
Actions of heparin that may affect the malignant process.
Cancer. 1999 Jan 15;85(2):257-72
PMID: 10023691
-
The use of heparin for treating human malignancies.
Haemostasis. 1999 Dec;29 Suppl S1:48-60
PMID: 10629404
-
Heparin and cancer.
Thromb Haemost. 1998 Jul;80(1):10-23
PMID: 9684778
-
Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.
Thromb Haemost. 1999 Aug;82(2):947-52
PMID: 10605808
-
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
Eur J Cancer. 1997 Jul;33(8):1209-15
PMID: 9301444